Olaparib
Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), marketed as Lynparza and developed under the codes AZD2281 and KU59436.
Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP), marketed as Lynparza and developed under the codes AZD2281 and KU59436. It is an orally administered targeted anticancer drug, used both as maintenance therapy after platinum-based chemotherapy and in combination regimens across ovarian, breast, prostate and pancreatic cancers.
The drug binds the catalytic site of PARP1 and the related enzyme PARP2, blocking the poly(ADP-ribosyl)ation that recruits repair factors to single-strand breaks, and — more consequentially — traps the enzyme on the DNA it has bound. A trapped PARP is a worse lesion than an absent one: the stalled complex collapses the oncoming replication fork into a double-strand break that is particularly dependent on homologous recombination for accurate repair. Tumors deficient in that pathway, most characteristically those with germline or somatic pathogenic variants in BRCA1 or BRCA2 and more broadly those scored as homologous recombination deficiency (HRD)-positive, cannot compensate, so the drug is selectively lethal to them while sparing repair-proficient tissue. This synthetic-lethal relationship underlies both its indications and the use of BRCA testing as a companion diagnostic.
The same dependence on the DNA damage response explains its use alongside DNA-damaging and antiangiogenic agents — the platinum drugs cisplatin and carboplatin, taxanes such as paclitaxel, temozolomide, radiotherapy and bevacizumab — and its pairing in prostate cancer with abiraterone plus prednisone or prednisolone, a regimen established in trials, unlike combination with enzalutamide. It is also combined with immune checkpoint blockade such as the anti-PD-L1 antibody durvalumab. Resistance arises through reversion mutations that restore homologous recombination, loss of the trapping-sensitive target, drug efflux via p-glycoprotein, restored fork protection, and adaptive responses including autophagy; response has been inconsistent in tumors that appear PARP-inhibitor-sensitive on other grounds, such as Ewing sarcoma. Common toxicities — myelosuppression, fatigue and gastrointestinal effects — reflect action on proliferating tissue, and prolonged exposure carries a small risk of myelodysplastic syndrome or acute myeloid leukemia.
Where the papers sit
21 papers from the last 6 months study olaparib directly · updated from PubMed 16 Nov 2026
Study type 4 clinical trials · 5 observational · 3 human data · 9 preclinical
Themes one subject · 1 paradigm shift · 1 new direction
Those 21 are all about one subject.
-
PARP Inhibition in Cancer
PARP inhibition is moving toward biomarker-selected use across ovarian, prostate, breast, endometrial, cervical, and small-cell lung cancers. BRCA mutations and broader HRD features recur as predictors of benefit, while pembrolizumab, bevacizumab, cediranib, and chemotherapy combinations extend investigation beyond maintenance monotherapy. Acquired resistance is linked to ferroportin deficiency and cGAS-STING-STAT3 survival signaling. Clinical outcomes, safety, cost-effectiveness, biomarkers, drug stability, and analytical testing remain central to translation.
Tumor-state mechanisms can override olaparib sensitivity, making PARP inhibition alone insufficient
Ovarian cancer models with ferroportin deficiency and Ewing sarcoma cells with active autophagy each show that olaparib response can be defeated by tumor-intrinsic survival mechanisms rather than determined solely by the drug’s PARP-inhibitory rationale. The ovarian cancer study links ferroportin loss to a cGAS-STING-STAT3 survival axis and evaluates ferroptosis induction or STING inhibition as ways to counter resistance, while the Ewing sarcoma study identifies autophagy as an impairment of PARP-inhibitor sensitivity after the drug failed to produce substantial clinical responses in that disease. Together, these findings shift the implication from using olaparib as a sufficient treatment strategy to identifying and targeting resistance states alongside it. 42968661Nov 42215796May
Olaparib is identified as a direct SIRT3-binding molecule in an ATM-deficient mitochondrial-dysfunction context
The integrated computational and SPR-based study of FDA-approved drugs for SIRT3 binding in an ataxia-telangiectasia context found that olaparib bound recombinant SIRT3 with a dissociation constant of 84 ± 5.7 nM, rather than treating it only as a PARP inhibitor in cancer therapy. This gives olaparib a distinct target-engagement and repurposing role in the study’s mitochondrial-homeostasis framework, expanding its use beyond the therapeutic and analytical categories represented by the other papers 42447746Jul.
Papers
The 21 papers from the last 6 months that study olaparib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
PARP Inhibition in Cancer (21)
- Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. Clinical and translational medicine · 2 Nov 2026 PMID 42968661
- Integration of In Silico Degradation Prediction, Mechanistic Stress Testing, and Accelerated Stability Modeling for Olaparib Drug Substance and Prototype Formulation. AAPS PharmSciTech · 28 Oct 2026 PMID 42946868
- Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012. Cancer · 14 Oct 2026 PMID 42870635
- Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705254
- Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status. International journal of urology : official journal of the Japanese Urological Association · 28 Aug 2026 PMID 42661511
- Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations - Real-world experience from Taiwan. Taiwanese journal of obstetrics & gynecology · 25 Aug 2026 PMID 42642151
- DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. Journal for immunotherapy of cancer · 14 Aug 2026 PMID 42601174
- Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531373
- Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model. Scientific reports · 29 Jul 2026 PMID 42527451
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
- Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 22 Jul 2026 PMID 42484750
- An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders. Bioorganic chemistry · 14 Jul 2026 PMID 42447746
- Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database. World journal of urology · 14 Jul 2026 PMID 42446704
- Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States. Urologic oncology · 10 Jul 2026 PMID 42431822
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial. British journal of cancer · 8 Jul 2026 PMID 42420629
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study. Radiology and oncology · 26 Jun 2026 PMID 42359758
- Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer. Journal of medicinal chemistry · 17 Jun 2026 PMID 42304805
- Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitors. Cancer chemotherapy and pharmacology · 29 May 2026 PMID 42215796
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
- Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness). Breast cancer (Tokyo, Japan) · 23 May 2026 PMID 42176176
By study type
Clinical trials (4)
- Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012. Cancer · 14 Oct 2026 PMID 42870635
- Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology · 7 Sept 2026 PMID 42705254
- DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. Journal for immunotherapy of cancer · 14 Aug 2026 PMID 42601174
- Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial. British journal of cancer · 8 Jul 2026 PMID 42420629
Observational studies and case reports (5)
- Real-World Outcomes of Olaparib in Japanese Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of BRCA2 Loss and Microsatellite Instability Status. International journal of urology : official journal of the Japanese Urological Association · 28 Aug 2026 PMID 42661511
- Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations - Real-world experience from Taiwan. Taiwanese journal of obstetrics & gynecology · 25 Aug 2026 PMID 42642151
- Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database. World journal of urology · 14 Jul 2026 PMID 42446704
- Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States. Urologic oncology · 10 Jul 2026 PMID 42431822
- Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness). Breast cancer (Tokyo, Japan) · 23 May 2026 PMID 42176176
Human data, design not indexed (3)
- Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jul 2026 PMID 42531373
- Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 22 Jul 2026 PMID 42484750
- An integrated in silico and SPR-based workflow identifies FDA-approved drugs as previously unrecognized SIRT3 binders. Bioorganic chemistry · 14 Jul 2026 PMID 42447746
Preclinical: animal, cell and lab studies (9)
- Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. Clinical and translational medicine · 2 Nov 2026 PMID 42968661
- Integration of In Silico Degradation Prediction, Mechanistic Stress Testing, and Accelerated Stability Modeling for Olaparib Drug Substance and Prototype Formulation. AAPS PharmSciTech · 28 Oct 2026 PMID 42946868
- Genomic profiling identifies actionable DNA-repair defects in a new cervical cancer model. Scientific reports · 29 Jul 2026 PMID 42527451
- Development of a stability-indicating RP-UPLC method for simultaneous determination of Abemaciclib and Olaparib with LC-MS characterization of degradation products and in vitro performance evaluation. Journal of chromatographic science · 23 Jul 2026 PMID 42490602
- Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
- Electroporation as a strategy to improve the efficacy of chemotherapy in neuroblastoma: an in vitro study. Radiology and oncology · 26 Jun 2026 PMID 42359758
- Integrating Machine Learning and Structure-Guided Discovery of a Novel Type II SYK Inhibitor for Treating Triple-Negative Breast Cancer. Journal of medicinal chemistry · 17 Jun 2026 PMID 42304805
- Autophagy impairs the sensitivity of Ewing sarcoma cells to PARP inhibitors. Cancer chemotherapy and pharmacology · 29 May 2026 PMID 42215796
- Molecular Boomerangs Against Cancer: Design, Synthesis, Biological Evaluation, and In Silico Study of Novel Dual PARP-1/EGFR Inhibitors. Drug development research · 28 May 2026 PMID 42207930
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-07-02. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.